Multiplatform Pipeline
Transactions & Partnerships
In July 2024, Orum entered a multi-target license and option agreement with Vertex Pharmaceuticals. Vertex will use Orum’s proprietary DAC technology for the discovery of novel targeted conditioning agents for use with gene editing and has the right to take up to three options.
Partnering with Orum
Are you interested in any of our pipeline assets or have targets and antibodies that might work well with our GSPT1 degrader payloads? Or have you developed degraders that need a better therapeutic index via antibody delivery?
Orum is ready to discuss a variety of different collaboration possibilities across our platform technologies and assets. Please contact us and let us know how we can work together.
Meet the Orum team at the following upcoming conferences:
China Healthcare Summit, Shanghai | November 2-4
BIO Europe, Cologne | November 9-11
Jeffries Global Healthcare Conference, London | November 16-19
ASH, New Orleans | December 12-15
JP Morgan Healthcare Conference, San Francisco | January 11-14